One Way Holdings LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 5.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 269,752 shares of the medical device company’s stock after selling 15,467 shares during the period. One Way Holdings LLC’s holdings in DexCom were worth $23,277,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 15.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after purchasing an additional 1,515,702 shares during the last quarter. Janus Henderson Group PLC boosted its position in DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after purchasing an additional 645,534 shares during the period. Legal & General Group Plc acquired a new position in DexCom during the 2nd quarter valued at approximately $173,237,000. Arrowstreet Capital Limited Partnership grew its stake in DexCom by 100.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in DexCom during the 2nd quarter worth $164,035,000. Institutional investors own 97.75% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the stock. Weiss Ratings upgraded shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, October 6th. Argus upped their target price on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. UBS Group raised their price target on shares of DexCom from $102.00 to $107.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen reaffirmed a “buy” rating and set a $95.00 price target on shares of DexCom in a report on Friday, September 18th. Finally, Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $93.70.
View Our Latest Stock Report on DexCom
Insider Transactions at DexCom
In related news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares of the company’s stock, valued at $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the transaction, the director directly owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 22,822 shares of company stock worth $1,920,193. Corporate insiders own 0.28% of the company’s stock.
DexCom Stock Performance
DXCM stock opened at $82.29 on Monday. The company has a 50-day simple moving average of $85.82 and a 200 day simple moving average of $74.65. The company has a market capitalization of $30.69 billion, a P/E ratio of 32.27, a PEG ratio of 1.37 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59.
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. DexCom’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Sell-side analysts predict that DexCom, Inc. will post 2.67 earnings per share for the current fiscal year.
About DexCom
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.
The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.
Read More
- Five stocks we like better than DexCom
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
